Eli Lilly and Company (NYSE:LLY) Shares Climb 1.2% – What’s Next?

Shares of Eli Lilly and Company (NYSE:LLY) shot up 1.2% on Friday. The company traded as high as $1,449.64 and last traded at $1,444.05. Approximately 1,861,846 shares traded hands during trading, a decline of 37% from the average session volume of 2,956,564 shares. The stock had previously closed at $1,427.28.

Trending Headlines about Eli Lilly and Company

Here are a few of the latest headlines about LLY:

• Positive Sentiment: Lilly broke ground on a $3.5 billion Pennsylvania plant intended to expand production of next-generation obesity medicines, including investigational retatrutide. The facility is part of a broader U.S. manufacturing expansion, but is expected to begin operations in 2031, so the added capacity is a longer-term catalyst. Lilly announcement on Pennsylvania manufacturing site
• Neutral Sentiment: Lilly’s early-stage ALS drug study is advancing, but the report offers no clinical results yet, leaving the potential impact on the company’s pipeline uncertain. Eli Lilly advances early ALS drug study
• Negative Sentiment: China Merchants Securities downgraded Lilly from “buy” to “hold,” a cautious analyst signal that may temper enthusiasm after the stock’s strong run. China Merchants Securities downgrades Eli Lilly

Analysts Set New Price Targets

Several research firms have recently issued reports on LLY. Wells Fargo & Company raised their target price on shares of Eli Lilly and Company from $1,330.00 to $1,500.00 and gave the stock an “overweight” rating in a report on Friday, October 30th. Leerink Partners increased their price objective on shares of Eli Lilly and Company from $1,309.00 to $1,316.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 21st. China Merchants Securities lowered shares of Eli Lilly and Company from a “buy” rating to a “hold” rating in a research report on Thursday. TD Cowen reissued a “buy” rating and issued a $1,250.00 price objective on shares of Eli Lilly and Company in a research note on Tuesday, September 22nd. Finally, BMO Capital Markets restated an “outperform” rating and set a $1,650.00 target price on shares of Eli Lilly and Company in a research report on Friday, October 30th. One investment analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Eli Lilly and Company currently has a consensus rating of “Moderate Buy” and an average price target of $1,416.64.

Eli Lilly and Company Stock Performance

The firm has a market capitalization of $1.36 trillion, a P/E ratio of 46.87, a P/E/G ratio of 1.72 and a beta of 0.40. The company has a debt-to-equity ratio of 1.17, a current ratio of 1.39 and a quick ratio of 1.00. The firm has a 50-day moving average price of $1,236.58 and a two-hundred day moving average price of $1,108.27.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Thursday, October 29th. The company reported $7.48 EPS for the quarter, topping analysts’ consensus estimates of $5.71 by $1.77. The firm had revenue of $24.40 billion for the quarter, compared to analysts’ expectations of $22.58 billion. Eli Lilly and Company had a net margin of 31.90% and a return on equity of 86.76%. The business’s revenue for the quarter was up 38.6% on a year-over-year basis. During the same period in the prior year, the business posted $7.02 earnings per share. On average, analysts forecast that Eli Lilly and Company will post 35.70 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, December 10th. Shareholders of record on Friday, November 13th will be given a $1.73 dividend. This represents a $6.92 annualized dividend and a yield of 0.5%. The ex-dividend date of this dividend is Friday, November 13th. Eli Lilly and Company’s payout ratio is 22.46%.

Insider Transactions at Eli Lilly and Company

In other news, EVP Anat Hakim sold 5,000 shares of the firm’s stock in a transaction that occurred on Monday, November 2nd. The shares were sold at an average price of $1,402.52, for a total transaction of $7,012,600.00. Following the transaction, the executive vice president directly owned 4,137 shares of the company’s stock, valued at approximately $5,802,225.24. This trade represents a 54.72% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Patrik Jonsson sold 6,500 shares of Eli Lilly and Company stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $1,175.10, for a total transaction of $7,638,150.00. Following the sale, the executive vice president directly owned 54,147 shares of the company’s stock, valued at $63,628,139.70. This represents a 10.72% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.14% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Eli Lilly and Company

Institutional investors and hedge funds have recently bought and sold shares of the company. New World Advisors LLC lifted its holdings in shares of Eli Lilly and Company by 12.2% in the 3rd quarter. New World Advisors LLC now owns 955 shares of the company’s stock worth $1,105,000 after buying an additional 104 shares during the period. State Board of Administration of Florida Retirement System grew its position in shares of Eli Lilly and Company by 7.5% during the 3rd quarter. State Board of Administration of Florida Retirement System now owns 734,302 shares of the company’s stock worth $849,646,000 after buying an additional 50,916 shares in the last quarter. Dock Street Asset Management Inc. increased its stake in shares of Eli Lilly and Company by 119.1% during the third quarter. Dock Street Asset Management Inc. now owns 2,439 shares of the company’s stock valued at $2,822,000 after buying an additional 1,326 shares during the period. Sonoma Allocations LLC increased its stake in shares of Eli Lilly and Company by 1.8% during the third quarter. Sonoma Allocations LLC now owns 1,247 shares of the company’s stock valued at $1,431,000 after buying an additional 22 shares during the period. Finally, Banco de Sabadell S.A raised its holdings in shares of Eli Lilly and Company by 1.4% in the third quarter. Banco de Sabadell S.A now owns 4,307 shares of the company’s stock valued at $4,987,000 after acquiring an additional 59 shares in the last quarter. 82.53% of the stock is owned by institutional investors.

Eli Lilly and Company Company Profile

Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for people and animals. Its work spans areas including diabetes and obesity, cancer, immunology, neuroscience and pain management. The company’s medicines include treatments for diabetes and obesity, such as Mounjaro and Zepbound, as well as products for cancer and other conditions. Lilly also conducts research into new medicines and invests in the development of treatments across its therapeutic areas.